We are live on ! Find out more
BBH icon

VanEck Biotech ETF

82 hedge funds and large institutions have $75.4M invested in VanEck Biotech ETF in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

654% more call options, than puts

Call options by funds: $1.82M | Put options by funds: $241K

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more funds holding

Funds holding: 82 → 82 (0)

9.71% less ownership

Funds ownership: 26.63% → 16.92% (-9.7%)

43% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 28

94% less capital inflows, than outflows

Capital inflows: $6.82M | Capital outflows: $107M

Holders
82
Holders Change
–
Holders Change %
0%
% of All Funds
1.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
16
Reduced
28
Closed
14
Calls
$1.82​M
Puts
$241​K
Net Calls
+$1.58​M
Net Calls Change
+$1​M

BBH Hedge Fund Activity: Q1 2018 in Review

82 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2018, worth a combined $75.4M — down 58% from $179M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BBH positions and 14 closed out — a net gain of 1 holder — while 16 added to existing stakes and 28 trimmed.

The largest buyer was Aspiriant LLC, opening a new position worth an estimated $1.43M. The largest seller was AllianceBernstein, exiting entirely with an estimated $77.8M sold.

  • 82 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $75.4M of VanEck Biotech ETF stock for Q1 2018, down 58% quarter-over-quarter.
  • 15 funds opened new VanEck Biotech ETF positions in Q1 2018 and 14 closed out, a net change of +1 holder.
  • The largest VanEck Biotech ETF buyer in Q1 2018 was Aspiriant LLC, an estimated $1.43M added.
  • The largest VanEck Biotech ETF seller in Q1 2018 was AllianceBernstein, an estimated $77.8M sold.

Based on aggregated 13F filings for Q1 2018.